hsa‑miR‑15a‑5p inhibits colon cell carcinoma via targeting CCND1.


Journal

Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259

Informations de publication

Date de publication:
10 2021
Historique:
received: 20 05 2020
accepted: 09 02 2021
entrez: 20 8 2021
pubmed: 21 8 2021
medline: 14 1 2022
Statut: ppublish

Résumé

Colon carcinoma is one of the most common cancers worldwide. Epidemiological studies have revealed that colon cancer is the third leading cause of cancer‑related deaths, which is due to the increased incidence and mortality rates. However, the treatment strategies for colon cancer remain unsatisfactory for patients, especially for those with advanced or recurrent colon cancer. Dysregulated microRNAs (miRNAs) are considered to influence tumor development and metastasis. However, the molecular mechanism through which miRNAs affect cancer progression is not yet completely understood. The aim of the present study was to investigate the expression levels of has‑miR‑15a‑5p and its molecular mechanism in colon cell carcinoma. In the present study, the expression levels of hsa‑miR‑15a‑5p were found to be decreased in colon tumor tissues and cancer cell lines. Hsa‑miR‑15a‑5p overexpression inhibited colon cell proliferation and migration. Mechanistically, the G1/S‑specific cyclin‑D1 (CCND1) gene was predicted as a target of hsa‑miR‑15a‑5p, as evidenced by bioinformatics and dual‑luciferase reporter assay analyses. CCND1 overexpression significantly increased the progression of colon cancer. Furthermore, CCND1 was demonstrated to mediate the effects of hsa‑miR‑15a‑5p on colon cancer cells. The present study demonstrated that hsa‑miR‑15a‑5p alleviated the proliferation, migration and invasion of colon cancer by targeting the CCND1 gene, which represents a potential molecular target for the diagnosis and treatment of colon cancer.

Identifiants

pubmed: 34414457
doi: 10.3892/mmr.2021.12375
pii: 735
pmc: PMC8404101
doi:
pii:

Substances chimiques

CCND1 protein, human 0
MIRN15 microRNA, human 0
MicroRNAs 0
Cyclin D1 136601-57-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Aging (Albany NY). 2020 Jan 25;12(2):1304-1321
pubmed: 31982864
Mol Med Rep. 2015 Nov;12(5):7396-402
pubmed: 26458302
Am J Physiol Gastrointest Liver Physiol. 2020 Apr 1;318(4):G827-G839
pubmed: 32174132
Cell Death Differ. 2010 Feb;17(2):215-20
pubmed: 19498445
JAMA. 2008 Jan 30;299(4):425-36
pubmed: 18230780
Gastroenterology. 2013 Nov;145(5):1064-1075.e11
pubmed: 23891973
Adv Exp Med Biol. 2013;774:39-53
pubmed: 23377967
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Biol Chem. 2010 Nov 12;285(46):35293-302
pubmed: 20826792
Onco Targets Ther. 2016 Oct 11;9:6247-6255
pubmed: 27785072
Oncol Res Treat. 2017;40(7-8):423-429
pubmed: 28683441
Cell Physiol Biochem. 2018;49(4):1289-1303
pubmed: 30205383
J Cancer Res Ther. 2014 Jul-Sep;10(3):531-4
pubmed: 25313733
Genes Cancer. 2018 Jan;9(1-2):53-65
pubmed: 29725503
Nat Rev Cancer. 2009 Apr;9(4):293-302
pubmed: 19262572
Asian Pac J Cancer Prev. 2013;14(12):7421-6
pubmed: 24460313
Hum Mol Genet. 2012 May 15;21(10):2157-65
pubmed: 22328083
JAMA Surg. 2017 May 1;152(5):452-459
pubmed: 28122072
Oncogene. 2017 Jun 15;36(24):3477-3489
pubmed: 28114282
Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9222-9229
pubmed: 31773673
Mol Biol Rep. 2019 Oct;46(5):5251-5256
pubmed: 31321645
Mol Med Rep. 2019 Jan;19(1):719-726
pubmed: 30431107
J Cancer Res Ther. 2014 Oct-Dec;10(4):1052-6
pubmed: 25579553
Oncotarget. 2015 Oct 20;6(32):32586-601
pubmed: 26452129
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Surg Oncol. 2017 Apr;115(5):619-630
pubmed: 28194798
Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4230-4235
pubmed: 27831653

Auteurs

Zhipeng Li (Z)

Department of Integrated Traditional Chinese and Western Medicine, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.

Zeyu Zhu (Z)

Department of Orthopedics, Huaian Hospital, Huaian, Jiangsu 223200, P.R. China.

Yanjun Wang (Y)

Department of Women's Preventive Health, Huishan No. 2 People's Hospital, Wuxi, Jiangsu 214400, P.R. China.

Ying Wang (Y)

Department of Radiotherapy, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.

Weibing Li (W)

Department of Integrated Traditional Chinese and Western Medicine, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.

Zhigang Wang (Z)

Department of Hospital Quality Management, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.

Xinyuan Zhou (X)

Department of Gastroenterology, Wuxi Hospital of TCM, Affiliated to Nanjing University of Chinese Medicine, Wuxi, Jiangsu 214000, P.R. China.

Yuhua Bao (Y)

Department of Integrated Traditional Chinese and Western Medicine, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH